There are no significant limitations post-treatment
Tirzepatide itself is a 39-amino-acid dual GIP/GLP-1 receptor agonist with a fatty-acid side chain that extends its half-life to roughly five days, supporting weekly subcutaneous dosing (Bastin & Andreassen, 2023)
Zepbound (tirzepatide) is FDA-approved for weight loss and weight management in adults with obesity, or in overweight adults with at least one weight-related medical condition
Yes, thats why our abstract title asks, Too much of a good thing? When Im talking to patients about going on these drugs, theyre like, I dont want to go on another medicine. I say, You know what
Our team can help you figure out what your body truly needs based on your labs, symptoms, and long-term goals
Studies were not designed to systematically assess blood pressure and randomization was not stratified based on baseline status of hypertension, SBP and other relevant parameters that could have affected the outcomes